uBriGene to Present at ESGCT 2026

October 27, 2026

uBriGene to Showcase Cell and Gene Therapy Innovations at ESGCT 2026

uBriGene Biosciences will attend the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 27–30, 2026, in Hamburg, Germany. Bringing together the gene and cell therapy community to exchange scientific advances and explore emerging technologies, ESGCT offers a valuable platform for innovation and collaboration.

uBriGene will showcase its technology platforms through two poster presentations spanning in vivo CAR-T development and circRNA-LNP-based iPSC reprogramming. These presentations reflect uBriGene’s commitment to advancing next-generation cell and gene therapy technologies and supporting innovators as they move advanced therapy medicinal products (ATMPs) from concept toward commercialization.

The posters will be presented at the following times:

Wednesday, October 28 | 13:30 - High-Yield In Vivo CAR-T Development Enabled by CD7 Nanobody and Detargeted Cocal-G Lentiviral Vectors
Thursday, October 29 | 14:00 - The Best-in-Class PBMC iPSC Reprogramming Kit via circRNA-LNP

As a cell and gene therapy-focused CRDMO, uBriGene provides integrated research, development, and manufacturing capabilities to help clients address complex challenges across the therapeutic development journey. By combining scientific expertise with quality-driven execution and client-centric collaboration, uBriGene aims to bridge the gap between ATMP innovation and commercialization.

Connect with uBriGene at ESGCT 2026

Are you developing next-generation cell therapies, optimizing viral vector platforms, or exploring RNA-based technologies? Connect with uBriGene to discuss your program needs and explore potential collaboration opportunities.